Further heterogeneity has been reported within Tregs present in the tumor, which is characterized by the expression of activation molecules such as TNF receptor superfamily member 9 (TNFRSF9) and Interleukin 1 receptor type 2 (IL1R2). This evidence concerns the gene IL1R2 and neoplasm.